Increased research and development investment, coupled with the costs of remediating quality issues at its facilities, contributed to Wockhardt posting a pre-tax loss • Source: Shutterstock
Stay ahead of every shift in generics and biosimilars.
Generics Bulletin brings you the latest updates that matter for the off-patent industry.
